Online Database of Chemicals from Around the World

(+/-)-美沙酮
[CAS# 76-99-3]

供应商
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Achemo Scientific Limited 香港 询价快递  
+852 3174-6428
sales@achemo.com
化学品生产商(2010 年起)
Alfa Chemistry 美国 询价快递  
+1 (201) 478-8534
inquiry@alfa-chemistry.com
化学品供销商(2012 年起)
chemBlink 标准供应商(2012 年起)
Alsachim SAS 法国 询价快递  
+33 (368) 240-080
contact@alsachim.com
化学品生产商
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
International Laboratory Limited 美国 询价快递  
+1 (650) 278-9963
admin@intlab.org
化学品生产商(2002 年起)
LGC Standards 英国 询价快递  
+44 (20) 8943-8480
uksales@lgcstandards.com
化学品生产商(2007 年起)
RIA International LLC 美国 询价快递  
+1 (973) 581-1282/
marketing@riausa.net,nj@riausa.net
化学品供销商
ZereneX Molecular Ltd. 英国 询价快递  
+44 (1204) 527-700
sales@zerenex-molecular.com
化学品生产商
基本信息
产品名称 (+/-)-美沙酮
英文名 (+/-)-Methadone
别名 Brn 3213667; Dextromethadone; 6-(Dimethylamino)-4,4-Diphenylheptan-3-One
分子结构 CAS 登录号:76-99-3, (+/-)-美沙酮
分子式 C21H27NO
分子量 309.45
CAS 登录号 76-99-3 (125-58-6;297-88-1;5653-80-5)
EINECS 登录号 200-996-9
分子行输入简码 SMILES C1=CC=CC=C1C(C2=CC=CC=C2)(C(CC)=O)CC(N(C)C)C
国际化学标识码 InChI 1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
国际化学标识检索码 InChIKey USSIQXCVUWKGNF-UHFFFAOYSA-N
物理化学性质
密度 1.0±0.1g/cm3 (计算值)
沸点 423.7±45.0°C at 760 mmHg (计算值)
闪点 126.5±19.8°C (计算值)
安全数据
受管制化学品 DEA 药物编码: 9250 说明
CSA 分类: 第 II 类
是否麻醉品? 是
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览(+/-)-美沙酮市场分析报告总目录
相关产品
去甲基-甲基对硫磷  (E)-3-(3H-咪唑-4-基)丙-2-烯酸  [4-[(4-二乙基氨基苯基)-苯基亚甲基]-1-...  Acnistin E  3-[[6-[(3-乙氧羰基-2,4,6-三碘苯基...  2-氨基-3-[(3E)-3-[[4-[(2S)-...  (2S)-2-[[(2S)-2-[[2-[[2-[...  5-[(4-二甲基氨基苯基)亚甲基]-1-(2-羟...  2-氨基-2-(5-甲基-3-氧代-1,2-恶唑-...  2-氨基-3-(3-氧代-1,2-恶唑-4-基)丙...  芬哌酰胺  Acnistin A  1,1-二(乙烯基)环己烷  3-氯-4-氧代戊酸  氯异桑大明